当前位置： SCI文献检索 > NEURO-ONCOLOGY期刊下所有文献 > Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Abstract：

BACKGROUND:We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS:Patients 22 years of age or less with recurrent ependymoma were treated with bolus dosage 5-FU weekly for 4 weeks followed by a 2-week rest period, defining one cycle. Patients could continue on therapy for 16 cycles. The starting 5-FU dosage was 500 mg/m(2). Dose-limiting toxicity was determined after one cycle. Patients were initially enrolled according to a rolling-6 design; subsequent dose re-escalation phase was based on a 3 + 3 design. RESULTS:We treated patients at 400 (n = 6), 500 (n = 15), and 650 (n = 5) mg/m(2), with de-escalation due to toxicity. Twenty-three of twenty-six patients enrolled were evaluable. Five patients experienced grade 4 neutropenia (n = 2: 650 mg/m(2); n = 3: 500 mg/m(2)). One patient experienced grade 3 diarrhea. At 500 mg/m(2), the median 5-FU maximal concentration, AUC0-∞, and alpha half-life were 825 µM, 205 µM × h, and 9.9 min, respectively. Interim analysis revealed an association between hematologic toxicity and prior number of chemotherapeutic regimens (P = .03). The study was amended to re-escalate the dosage in a less heavily pretreated cohort of patients. CONCLUSIONS:These phase I clinical data provide initial pharmacokinetic parameters to describe i.v. bolus 5-FU disposition in children with recurrent ependymoma. Tumor exposures effective in preclinical testing can be achieved with tolerable bolus dosages in patients. Bolus 5-FU is well tolerated and possesses antitumor activity.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Wright KD,Daryani VM,Turner DC,Onar-Thomas A,Boulos N,Orr BA,Gilbertson RJ,Stewart CF,Gajjar A

doi

10.1093/neuonc/nov181

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

1620-7

issue

12

eissn

1522-8517

issn

1523-5866

pii

nov181

journal_volume

17

pub_type

杂志文章

相关文献

NEURO-ONCOLOGY文献大全
  • Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.

    abstract：Background:Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the diagnostic accuracy of 2HG single-voxel spectroscopy (SVS) and chemical shift imaging (CSI) in both newly diagnosed and posttreatment settings. Methods...

    journal_title：Neuro-oncology

    pub_type： 临床试验,杂志文章

    doi：10.1093/neuonc/noy022

    authors： Zhou M,Zhou Y,Liao H,Rowland BC,Kong X,Arvold ND,Reardon DA,Wen PY,Lin AP,Huang RY

    更新日期：2018-08-02 00:00:00

  • Telomere maintenance and the etiology of adult glioma.

    abstract：:A growing body of epidemiologic and tumor genomic research has identified an important role for telomere maintenance in glioma susceptibility, initiation, and prognosis. Telomere length has long been investigated in relation to cancer, but whether longer or shorter telomere length might be associated with glioma risk ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/nov082

    authors： Walsh KM,Wiencke JK,Lachance DH,Wiemels JL,Molinaro AM,Eckel-Passow JE,Jenkins RB,Wrensch MR

    更新日期：2015-11-01 00:00:00

  • Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007.

    abstract：:An increase in the incidence of CNS tumors has been observed in many countries in the last decades. The reality of this trend has been much debated, as it has happened during a period when computer-assisted tomography and MRI have dramatically improved the detection of these tumors. The Gironde CNS Tumor Registry prov...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nor120

    authors： Baldi I,Gruber A,Alioum A,Berteaud E,Lebailly P,Huchet A,Tourdias T,Kantor G,Maire JP,Vital A,Loiseau H,Gironde TSNC Registry Group.

    更新日期：2011-12-01 00:00:00

  • Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced.

    abstract：:Histone deacetylase inhibitors that increase histone acetylation on transformed cells are being investigated as unique anticancer drugs. The aim of this investigation was to evaluate an antiproliferative activity of the histone deacetylase inhibitors sodium butyrate (NaBT) and trichostatin A on 5 glioma cell lines, T9...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/4.2.95

    authors： Kamitani H,Taniura S,Watanabe K,Sakamoto M,Watanabe T,Eling T

    更新日期：2002-04-01 00:00:00

  • Biology and management of ependymomas.

    abstract：:Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/now016

    authors： Wu J,Armstrong TS,Gilbert MR

    更新日期：2016-07-01 00:00:00

  • Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling.

    abstract：BACKGROUND:Accumulation and infiltration of microglia/brain macrophages around and into glioma tissue promote tumor invasion and expansion. One tumor-promoting mechanism of microglia/brain macrophages is upregulation of membrane type 1 matrix metalloprotease (MT1-MMP), which promotes the degradation of extracellular ma...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou324

    authors： Hu F,Dzaye O,Hahn A,Yu Y,Scavetta RJ,Dittmar G,Kaczmarek AK,Dunning KR,Ricciardelli C,Rinnenthal JL,Heppner FL,Lehnardt S,Synowitz M,Wolf SA,Kettenmann H

    更新日期：2015-02-01 00:00:00

  • Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

    abstract：:Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity. A total of 44 patients with glioblastoma with gros...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nos003

    authors： Ulmer S,Spalek K,Nabavi A,Schultka S,Mehdorn HM,Kesari S,Dörner L

    更新日期：2012-04-01 00:00:00

  • Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways.

    abstract：BACKGROUND:Resection of motor pathway gliomas requires the intraoperative recognition of essential cortical-subcortical motor structures. The degree of involvement of motor structures is variable, and increases as result of treatments patients are submitted to. Intraoperative neurophysiology offers various stimulation ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not327

    authors： Bello L,Riva M,Fava E,Ferpozzi V,Castellano A,Raneri F,Pessina F,Bizzi A,Falini A,Cerri G

    更新日期：2014-08-01 00:00:00

  • Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

    abstract：BACKGROUND:We recently demonstrated that brain endothelial cells and astrocytes protect cancer cells from chemotherapy through an endothelin-dependent signaling mechanism. Here, we evaluated the efficacy of macitentan, a dual endothelin receptor (ETAR and ETBR) antagonist, in the treatment of experimental breast and lu...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/now037

    authors： Lee HJ,Hanibuchi M,Kim SJ,Yu H,Kim MS,He J,Langley RR,Lehembre F,Regenass U,Fidler IJ

    更新日期：2016-04-01 00:00:00

  • Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

    abstract：Background:CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-c...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nox134

    authors： Levesley J,Steele L,Brüning-Richardson A,Davison A,Zhou J,Ding C,Lawler S,Short SC

    更新日期：2018-01-22 00:00:00

  • Paraneoplastic chorea: case study with autopsy confirmation.

    abstract：:A 67-year-old man presented with a 7-month history of insidiously progressive chorea, ataxia, and vertigo. Neurologic examination revealed deficits referable to the basal nuclei, cerebellar vermis, and vestibular nuclei. Small-cell lung cancer was diagnosed by fine-needle biopsy of a parahilar mass. After chemotherapy...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/4.3.192

    authors： Tremont-Lukats IW,Fuller GN,Ribalta T,Giglio P,Groves MD

    更新日期：2002-07-01 00:00:00

  • HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.

    abstract：BACKGROUND:Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noz215

    authors： Capdevielle C,Desplat A,Charpentier J,Sagliocco F,Thiebaud P,Thézé N,Fédou S,Hooks KB,Silvestri R,Guyonnet-Duperat V,Petrel M,Raymond AA,Dupuy JW,Grosset CF,Hagedorn M

    更新日期：2020-04-15 00:00:00

  • Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

    abstract：BACKGROUND:Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classification-however, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinico...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not125

    authors： Laxton RC,Popov S,Doey L,Jury A,Bhangoo R,Gullan R,Chandler C,Brazil L,Sadler G,Beaney R,Sibtain N,King A,Bodi I,Jones C,Ashkan K,Al-Sarraj S

    更新日期：2013-12-01 00:00:00

  • A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

    abstract：:Difficulties of drug delivery across the blood-brain barrier (BBB) and failure to eliminate cancer stem cells (CSCs) are believed to be the major causes of tumor recurrences in children with medulloblastoma (MB). Seneca Valley virus-001 (SVV-001) is a naturally occurring oncolytic picornavirus that can be systemically...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noq148

    authors： Yu L,Baxter PA,Zhao X,Liu Z,Wadhwa L,Zhang Y,Su JM,Tan X,Yang J,Adesina A,Perlaky L,Hurwitz M,Idamakanti N,Police SR,Hallenbeck PL,Blaney SM,Chintagumpala M,Hurwitz RL,Li XN

    更新日期：2011-01-01 00:00:00

  • Role of CX3CR1 signaling in malignant transformation of gliomas.

    abstract：BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noaa075

    authors： Lee S,Latha K,Manyam G,Yang Y,Rao A,Rao G

    更新日期：2020-10-14 00:00:00

  • Molecular and translational advances in meningiomas.

    abstract：:Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treat...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/noy178

    authors： Suppiah S,Nassiri F,Bi WL,Dunn IF,Hanemann CO,Horbinski CM,Hashizume R,James CD,Mawrin C,Noushmehr H,Perry A,Sahm F,Sloan A,Von Deimling A,Wen PY,Aldape K,Zadeh G,International Consortium on Meningiomas.

    更新日期：2019-01-14 00:00:00

  • Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

    abstract：BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not068

    authors： de Blank PM,Berman JI,Liu GT,Roberts TP,Fisher MJ

    更新日期：2013-08-01 00:00:00

  • A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

    abstract：:The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nor091

    authors： Kreisl TN,Zhang W,Odia Y,Shih JH,Butman JA,Hammoud D,Iwamoto FM,Sul J,Fine HA

    更新日期：2011-10-01 00:00:00

  • Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

    abstract：BACKGROUND:Anaplastic oligodendroglial tumors are rare, and median survival varies widely. Analysis of 1p19q deletion is performed commonly and is an important prognostic factor. However, age and other clinical variables also carry prognostic value, and it is unclear how to incorporate them into clinical decision makin...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou083

    authors： Panageas KS,Reiner AS,Iwamoto FM,Cloughesy TF,Aldape KD,Rivera AL,Eichler AF,Louis DN,Paleologos NA,Fisher BJ,Ashby LS,Cairncross JG,Urgoiti GB,Wen PY,Ligon KL,Schiff D,Robins HI,Rocque BG,Chamberlain MC,Mason WP,

    更新日期：2014-11-01 00:00:00

  • Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.

    abstract：Background:Depending on the level, differentiation state, and tumor stage, reactive nitrogen and oxygen species inhibit or increase cancer growth and tumor initiating cell maintenance. The rate-limiting enzyme in a pathway that can regulate reactive species production but has not been thoroughly investigated in gliobla...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noy012

    authors： Tran AN,Walker K,Harrison DG,Chen W,Mobley J,Hocevar L,Hackney JR,Sedaka RS,Pollock JS,Goldberg MS,Hambardzumyan D,Cooper SJ,Gillespie Y,Hjelmeland AB

    更新日期：2018-07-05 00:00:00

  • A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.

    abstract：:Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 e...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1093/neuonc/nop065

    authors： Gan HK,Rosenthal MA,Dowling A,Kalnins R,Algar E,Wong N,Benson A,Woods AM,Cher L

    更新日期：2010-05-01 00:00:00

  • The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.

    abstract：Background:Advances from glioma stemlike cell (GSC) research, though increasing our knowledge of glioblastoma (GBM) biology, do not influence clinical decisions yet. We explored the translational power of GSC-enriched cultures from patient-derived tumorspheres (TS) in predicting treatment response. Methods:The relatio...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/now304

    authors： D'Alessandris QG,Biffoni M,Martini M,Runci D,Buccarelli M,Cenci T,Signore M,Stancato L,Olivi A,De Maria R,Larocca LM,Ricci-Vitiani L,Pallini R

    更新日期：2017-08-01 00:00:00

  • The molecular profile of microglia under the influence of glioma.

    abstract：:Microglia, which contribute substantially to the tumor mass of glioblastoma, have been shown to play an important role in glioma growth and invasion. While a large number of experimental studies on functional attributes of microglia in glioma provide evidence for their tumor-supporting roles, there also exist hints in...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/nos116

    authors： Li W,Graeber MB

    更新日期：2012-08-01 00:00:00

  • Invasion patterns in brain metastases of solid cancers.

    abstract：BACKGROUND:Brain metastases are generally considered to be well demarcated from the surrounding brain parenchyma, although infiltrative growth patterns have been observed. We systemically investigated infiltration patterns and expression of adhesion molecules in a large and well-defined series of autopsy cases of brain...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not112

    authors： Berghoff AS,Rajky O,Winkler F,Bartsch R,Furtner J,Hainfellner JA,Goodman SL,Weller M,Schittenhelm J,Preusser M

    更新日期：2013-12-01 00:00:00

  • Response and progression in recurrent malignant glioma.

    abstract：:In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and...

    journal_title：Neuro-oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1093/neuonc/1.4.282

    authors： Hess KR,Wong ET,Jaeckle KA,Kyritsis AP,Levin VA,Prados MD,Yung WK

    更新日期：1999-10-01 00:00:00

  • Copy number profiling across glioblastoma populations has implications for clinical trial design.

    abstract：Background:Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noy108

    authors： Cimino PJ,McFerrin L,Wirsching HG,Arora S,Bolouri H,Rabadan R,Weller M,Holland EC

    更新日期：2018-09-03 00:00:00

  • Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.

    abstract：:The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)-PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controversial. The objectiv...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nos260

    authors： Corroyer-Dulmont A,Pérès EA,Petit E,Guillamo JS,Varoqueaux N,Roussel S,Toutain J,Divoux D,MacKenzie ET,Delamare J,Ibazizène M,Lecocq M,Jacobs AH,Barré L,Bernaudin M,Valable S

    更新日期：2013-01-01 00:00:00

  • Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

    abstract：:Angiogenesis plays a key role in glioblastoma biology and antiangiogenic agents are under clinical investigation with promising results. However, the angiogenic profiles of patients with glioblastoma and their clinical significance are not well understood. Here we characterize the serum angiogenic profile of patients ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noq170

    authors： Crocker M,Ashley S,Giddings I,Petrik V,Hardcastle A,Aherne W,Pearson A,Bell BA,Zacharoulis S,Papadopoulos MC

    更新日期：2011-01-01 00:00:00

  • Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.

    abstract：:PDGFRA is a critical gene in glioma biology. Similar to EGFR, PDGFRA has been shown to be overexpressed, amplified, mutated, or truncated in gliomas, particularly glioblastomas. In addition, PDGFRA has been recently shown to be rearranged in glioblastoma. However, the frequency, cooccurrence, and clinical value of PDG...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nos217

    authors： Alentorn A,Marie Y,Carpentier C,Boisselier B,Giry M,Labussière M,Mokhtari K,Hoang-Xuan K,Sanson M,Delattre JY,Idbaih A

    更新日期：2012-11-01 00:00:00

  • A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

    abstract：BACKGROUND:Both the epidermal growth factor receptor and vascular endothelial growth factor pathways are frequently overexpressed in glioblastoma multiforme. This study combined bevacizumab, a vascular endothelial growth factor inhibitor, and erlotinib, an epidermal growth factor receptor inhibitor, with standard radia...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou029

    authors： Clarke JL,Molinaro AM,Phillips JJ,Butowski NA,Chang SM,Perry A,Costello JF,DeSilva AA,Rabbitt JE,Prados MD

    更新日期：2014-07-01 00:00:00